354 Investors following Dolphin Medical. Share this News with them.
0
Like this story, share it with millions of investors on M3
Dolphin Medical in limelight due to major corp developments
Dolphin Medical Services counter has, of late, been active on expectation of major corporate developments. The stock has gained 48% in the last one month and the fortnightly average volume on the BSE is 6.17 lakh shares.
Dolphin Medical Services counter has, of late, been active on expectation of major corporate developments. The stock has gained 48% in the last one month and the fortnightly average volume on the BSE is 6.17 lakh shares.
The company has recently entered into an agreement with a nanotechnology company Biomix Network - an Indian outfit of a German company with operational base in Mumbai. Biomix, which has a range of products in the diagnostic, pharmaceuticals and healthcare sectors, is planning to take roughly around 5% stake in Dolphin, Mr S. Rao, Director, Dolphin, confirmed to Business Line.
Dolphin has the sole marketing and distribution rights for Biomix products in the country. Biomix also agreed to license its diagnostics and clinical trial software and activities to Dolphin.
The company has recently entered into an agreement with a nanotechnology company Biomix Network - an Indian outfit of a German company with operational base in Mumbai. Biomix, which has a range of products in the diagnostic, pharmaceuticals and healthcare sectors, is planning to take roughly around 5% stake in Dolphin, Mr S. Rao, Director, Dolphin, confirmed to Business Line.
